Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company dedicated to developing light and/or radiation activated small molecules for effectively destroying cancers, bacteria, and viruses. Their lead compound, RuvidarTM, has shown promise in inactivating various viruses and increasing efficacy in cancer cell destruction. Recent research has demonstrated RuvidarTM's ability to reverse the charge of BCG, creating a compound, RuBCG, with enhanced cancer cell kill rates. Additionally, Rutherrin® has proven effective in increasing chemotherapy efficacy and reducing multidrug resistance in cancer cells. Theralase is committed to advancing innovative therapies to combat challenging diseases and improve patient outcomes.
FAQ
What is the current stock price of Theralase Technologies (TLTFF)?
What is the market cap of Theralase Technologies (TLTFF)?
What is Theralase Technologies Inc. focused on?
What is RuvidarTM and its significance?
How does RuvidarTM impact BCG in cancer treatment?
What is the role of Rutherrin® in chemotherapy?
What is Theralase's commitment to innovation in healthcare?
